Core Insights - Zenas BioPharma is preparing to submit marketing applications for obexelimab for IgG4-RD to the FDA in Q2 2026 and to the EMA in H2 2026, following positive Phase 3 INDIGO trial results [1][4] - The company anticipates topline results from the Phase 2 SunStone trial for systemic lupus erythematosus (SLE) in Q4 2026 [1][4] - Zenas has secured up to $250 million in non-dilutive debt financing from Pharmakon, enhancing its financial flexibility for commercialization and pipeline investments [1][6] Corporate Highlights - Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, showing a 56% reduction in IgG4-RD flare risk compared to placebo in the INDIGO trial [4][12] - The company is advancing multiple pipeline programs, including orelabrutinib for multiple sclerosis (MS) and ZB021, an oral IL-17AA/AF inhibitor, with Phase 1 trials expected to start in Q2 2026 [2][3][7] - ZB014, a new half-life extended anti-CD-19 and FcγRIIb antibody, is also progressing toward clinical development [3][4] Financial Results - For the year ended December 31, 2025, Zenas reported revenue of $10 million, primarily from a license agreement, compared to $5 million in 2024 [10][11] - Research and development expenses increased to $168.1 million in 2025 from $139.1 million in 2024, driven by higher personnel and clinical trial costs [13][21] - The net loss for the year was $377.7 million, compared to a net loss of $157.0 million in 2024 [13][21] Balance Sheet - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $360.5 million, up from $350.8 million in 2024 [22] - Total liabilities increased to $141.5 million from $57.5 million in 2024, reflecting the new debt facility [22] - The accumulated deficit reached $765.1 million as of December 31, 2025, compared to $387.4 million in 2024 [22]